FDA approves Protagonist and Takeda’s drug for rare blood cancer

FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder

FDA approved Takeda & Protagonist's Mimrylo (rusfertide) for polycythemia vera, a rare blood disease.